Sign in
Taking people in United StatesPhase 2

A new medicine, EDG-15400, tested for a heart condition in adults

Tests EDG-15400 against a dummy pill in adults with heart failure and preserved pumping.

Key facts

Who runs it
Edgewise Therapeutics, Inc.
Where
Baltimore, Beverly Hills, Birmingham, Charleston, Charlottesville, Cincinnati, Dallas, Fort Wayne, Gainesville, Greensboro, Houma, Houston, Indianapolis, Jackson, Kansas City, Little Rock, Mechanicsburg, Minneapolis, New York, Peoria, San Diego, Seattle, St Louis, Tulsa, Vista, and Ypsilanti, United StatesSee the 28 sites
Trial code
Registry title
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
25 Aug 2026
Expected to end
Dec 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • EDG-15400 25 mg
  • Placebo to match EDG-15400 25 mg or 50 mg
  • EDG-15400 50 mg
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure with preserved ejection fraction (HFpEF) who have symptoms. It tests different doses of EDG-15400 against a placebo.

Age
30 to 84 years (at least 30 and under 85)
Sex
Men and women who are not pregnant
Disease stage
Heart failure with LVEF of 50% or more, and NYHA functional class II or III
Earlier treatment
If taking heart failure medicines, the doses must be stable. If taking a GLP-1 agonist, no dose change may be planned during the study.
Biomarker or test result
LVEF of 50% or more

Main reasons for not taking part

  • Known hypertrophic cardiomyopathy (HCM)
  • Known or suspected infiltrative or storage disorder, such as Noonan syndrome, Fabry disease or amyloidosis
  • Moderate or worse interstitial lung disease, or lung disease needing long-term extra oxygen
  • Severe or worse COPD, or COPD needing long-term extra oxygen
  • Hospital stay for any reason within 60 days before screening

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Males and nonpregnant females, ages ≥30 to <85 years of age at screening
  • Body weight ≥ 45 kg, BMI < 40
  • LVEF ≥ 50%
  • Diagnosed with Heart Failure per American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) Guidelines for the Management of Heart Failure
  • New York Heart Association (NYHA) functional class II or III
  • If receiving Guideline-directed Medical Therapy, must be on stable doses
  • Participants receiving a GLP-1 agonist prior to Screening must have no anticipated plans to change dose during the study

Who cannot take part

  • Hospitalization for any reason within 60 days prior to Screening
  • Known or suspected infiltrative or storage disorder (e.g., Noonan syndrome, Fabry disease, amyloidosis)
  • Moderate or greater interstitial lung disease (ILD) or ILD requiring chronic supplemental O2 therapy
  • Severe or greater chronic obstructive pulmonary disease (COPD) or COPD requiring chronic supplementary O2 therapy
  • History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the Investigator or the Medical Monitor, would be an alternative explanation for heart failure symptoms (e.g., significant lung disease, anemia) and/or would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion
  • Known diagnosis of hypertrophic cardiomyopathy (HCM)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 30 and 84 years old?

Where in United States

  • Baltimore, MarylandHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Beverly Hills, CaliforniaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Birmingham, AlabamaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Taking people
  • Charleston, South CarolinaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Charlottesville, VirginiaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Cincinnati, OhioHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Dallas, TexasHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Fort Wayne, IndianaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Gainesville, FloridaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Greensboro, North CarolinaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Houma, LouisianaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Taking people
  • Houston, TexasHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Indianapolis, IndianaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Jackson, MississippiHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Kansas City, MissouriHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Little Rock, ArkansasHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Mechanicsburg, PennsylvaniaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Minneapolis, MinnesotaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • New YorkHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Peoria, IllinoisHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Taking people
  • San Diego, CaliforniaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Seattle, WashingtonHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • St Louis, MissouriHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Tulsa, OklahomaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting
  • Vista, CaliforniaHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Taking people
  • Ypsilanti, MichiganHospital not named in the registryContact: Study Director: Medical Director, Edgewise Therapeutics, Inc.Not yet recruiting

About the trial

What the trial wants to find out

This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

The 3 groups in the trial

  • EDG-15400 25 mgTreatment being tested
  • EDG-15400 50 mgTreatment being tested
  • PlaceboPlacebo, for comparison

    Treatment: Placebo to match EDG-15400 25 mg or 50 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Plain-language title
A new medicine, EDG-15400, tested for a heart condition in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07795814, who can take part
Record updated
13 October 2026